Acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) is a life-threatening condition caused due to significant pulmonary and systemic inflammation. Chlorogenic acid (CGA) has been shown to possess potent antioxidant, anti-inflammatory, and immunoprotective properties. However, the protective effect of CGA on viral and bacterial-induced ALI/ARDS is not yet explored. Hence, the current study is aimed to evaluate the preclinical efficacy of CGA in lipopolysaccharide (LPS) and polyinosinic:polycytidylic acid (POLY I:C)-induced ALI/ARDS models in vitro and in vivo. Human airway epithelial (BEAS-2B) cells exposed to LPS+POLY I:C significantly elevated oxidative stress and inflammatory signaling. Co-treatment with CGA (10 and 50 µM) prevented inflammation and oxidative stress mediated by TLR4/TLR3 and NLRP3 inflammasome axis. BALB/c mice, when chronically challenged with LPS+POLY I:C showed a significant influx of immune cells, upregulation of pro-inflammatory cytokines, namely: IL-6, IL-1β, and TNF-α, and treatment with intranasal CGA (1 and 5 mg/kg) normalized the elevated levels of immune cell infiltration as well as pro-inflammatory cytokines. D-Dimer, the serum marker for intravascular coagulation, was significantly increased in LPS+ POLY I:C challenged animals which was reduced with CGA treatment. Further, CGA treatment also has a beneficial effect on the lung and heart, as shown by improving lung physiological and cardiac functional parameters accompanied by the elevated antioxidant response and simultaneous reduction in tissue damage caused by LPS+POLY I:C co-infection. In summary, these comprehensive, in vitro and in vivo studies suggest that CGA may be a viable therapeutic option for bacterial and viral-induced ALI-ARDS-like pathology.
Objective
Emergent epidemiological evidence suggests that the progression of NAFLD/NASH-associated HCC positively correlates with the patient's glycemic index. However, the mechanism behind this progressive pathological alteration is poorly understood. It has shown that the polyol pathway master regulator, AKR1B1 is over-expressed in hyperglycemia and responsible for most of diabetic complications. Hence in the present study, we have investigated the role of AKR1B1 in metabolic switching associated with NAFLD/NASH and in the progression of HCC.
Methods
The expression of AKR1B1 in NAFL/NASH, HCC, and HCC with diabetes mellitus patient's liver and plasma were estimated. The role of AKR1B1 in the metabolic switching of HCC cell lines was assessed through media conditioning and lentiviral transfection. Standard inhibitor epalrestat or investigational drug NARI-29 (4-((Z)-5-((Z)-2-Cyano-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl) benzoic acid) was utilized to elucidate the effect of AKR1B1 inhibition in hepatocarcinogenesis. A proteomic approach was applied for an in-depth investigation of the involved metabolic pathway and to evaluate the therapeutic efficacy of pharmacological inhibitors. Preclinically, a high fructose diet (HFrD) fed in combination with a diethyl nitrosamine (DEN) induced mouse model was developed to investigate the role of AKR1B1 in the hyperglycemia-mediated metabolic switching in the pathobiology of NAFLD and its progression to HCC.
Results
A significant increase in the expression of AKR1B1 was observed in NAFL/NASH, HCC, and HCC-DM tissue samples compared to non-involved adjacent tissues indicating its role in the disease progression. Moreover, a statistically significant elevation of AKR1B1 was observed in NAFLD, NAFLD-associated HCC, and HCC-DM plasma samples compared to normal control. Mechanistically, Invitro assays revealed that AKR1B1 modulates the Warburg effect, mitochondrial dynamics, TCA cycle, and lipogenesis to promote hyperglycemia-mediated fatty liver and cancer progression. A pathologically increased expression of AKR1B1 was observed in experimental NAFL-HCC, and expression was positively correlated with high blood glucose levels. HFrD + DEN-treated animals also exhibited statistically significant elevation of metabolic markers and carcinogenesis markers. However, AKR1B1 inhibition with EPS or NARI-29 has inhibited cellular metabolism in vitro and in vivo models.
Conclusion
Pathological AKR1B1 modulates hepatic glucose metabolism to promote NAFLD-associated hepato-carcinogenesis. Aldose reductase inhibition modulates glucose metabolism to prevent the pre-cancerous hepatocyte formation. Hence EPS and NARI-29 could be promising AKR1B1 inhibitors for controlling aberrant metabolism and treating NAFLD-associated HCC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.